Browsing by Author O'Callaghan, Chris

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2010Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabSimes, Robert John; Arena, Sabrina; Bardelli, Alberto; Cutsem, E Van; De Roock, Wendy; Di Nicolantonio, Federica; Frattini, Milo; Jonker, Derek J.; Karapetis, Christos; Khambata-Ford, Shirin; Lamba, Simona; O'Callaghan, Chris; Piessevaux, Hubert; Sartore-Bianchi, Andrea; Siena, Salvatore; Tejpar, Sabine; Tu, D.; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials CentreAssociation of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab, JAMA: The Journal of the American Medical Association, vol.304, 16,pp 1812-1820
2009Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.Pavlakis, Nick; Au, Heather-Jane; et al, various; Jefford, Michael; Karapetis, Christos; Kennecke, Hagen; Koski, Sherryl; Moore, M J; O'Callaghan, Chris; Shapiro, Jeremy; Tu, Dongsheng; Zalcberg, John; Northern Clinical School: MedicineHealth-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial., Journal of Clinical Oncology, vol.27, 11,pp 1822-1828
2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialSimes, Robert John; Tebbutt, Niall; Zalcberg, John; Au, Heather-Jane; Australasian Gastrointestinal Interest, Group; Colwell, Bruce; Evans, William K.; Findlay, Brian; Gibbs, Peter; Isogai, Pierre K.; Jonker, Derek J.; Karapetis, Christos; Links, Matthew; Mittman, Nicole; Moore, Malcolm; O'Callaghan, Chris; Siddiqui, Jehan; Tu, D.; Working Group on Economic Analysis of the National Cancer Institute of Canada, Clinical Trials Group; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreProspective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial, Journal of the National Cancer Institute, vol.101, 17, 2009,pp 1182-1192
2016Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II TrialMartin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Tsobanis, Eric; Wong, Ka (Mark); Yip, Sonia; Alcindor, Thierry; bang, Yungjue; Burnell, Margot J; Cho, Jaeyong; Goldstein, David; Kang, Yoon-Koo; Kim, Jinwon; Lee, Jeeyun; Lipton, Lara; O'Callaghan, Chris; Rha, Sunyoung; Strickland, A. H.; Tebbutt, Niall; Zalcberg, John; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); NH&MRC Clinical Trials CentreRegorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial, Journal of Clinical Oncology, vol.34, 23, 2016,pp 2728-2735